[SCHEDULE 13G/A] Aura Biosciences, Inc. SEC Filing
Aura Biosciences disclosure: Suvretta Capital Management, LLC, Averill Master Fund, Ltd. and Aaron Cowen report shared beneficial ownership positions in Aura Biosciences common stock. Suvretta and Aaron Cowen each report 4,701,775 shares (7.6% of the class); Averill Master Fund reports 4,137,797 shares (6.6% of the class). Each reporting person states no sole voting or dispositive power and reports shared voting and dispositive power for the stated shares. The filing describes pre-funded warrants exercisable subject to a Maximum Percentage cap of 9.99%, which may be increased to up to 19.99% with written notice effective after 61 days; as a result, not all warrants are presently exercisable and the number of shares issuable upon exercise may change with changes in outstanding common stock. The securities reported are directly owned by advisory clients of Suvretta, and the reporting persons disclaim beneficial ownership except to the extent of their pecuniary interest.
Divulgazione di Aura Biosciences: Suvretta Capital Management, LLC, Averill Master Fund, Ltd. e Aaron Cowen dichiarano posizioni di propriet脿 beneficiaria condivisa sulle azioni ordinarie di Aura Biosciences. Suvretta e Aaron Cowen riportano ciascuno 4,701,775 azioni (7.6% della classe); Averill Master Fund riporta 4,137,797 azioni (6.6% della classe). Ciascuna parte segnalante dichiara di non avere potere di voto o di disposizione esclusivo e indica di detenere congiuntamente il potere di voto e di disposizione sulle azioni indicate. Il deposito descrive warrant prefinanziati esercitabili soggetti a un limite di Percentuale Massima del 9.99%, che pu貌 essere aumentato fino al 19.99% tramite avviso scritto che diventa efficace dopo 61 giorni; di conseguenza non tutti i warrant sono attualmente esercitabili e il numero di azioni emettibili al momento dell'esercizio pu貌 variare con le modifiche delle azioni ordinarie in circolazione. I titoli segnalati sono di propriet脿 diretta dei clienti consuliti di Suvretta, e le persone che segnalano rinunciano a dichiarare la propriet脿 beneficiaria, salvo nella misura del loro interesse pecuniario.
Divulgaci贸n de Aura Biosciences: Suvretta Capital Management, LLC, Averill Master Fund, Ltd. y Aaron Cowen informan posiciones de propiedad beneficiaria compartida sobre acciones ordinarias de Aura Biosciences. Suvretta y Aaron Cowen informan cada uno de 4,701,775 acciones (7.6% de la clase); Averill Master Fund informa 4,137,797 acciones (6.6% de la clase). Cada persona declarantes se帽ala que no tiene poder exclusivo de voto o de disposici贸n y declara tener poderes compartidos de voto y de disposici贸n sobre las acciones indicadas. La presentaci贸n describe warrants prefinanciados ejercitables sujetos a un tope de Porcentaje M谩ximo del 9.99%, que puede incrementarse hasta 19.99% mediante aviso escrito que surte efecto despu茅s de 61 d铆as; por tanto, no todos los warrants son actualmente ejercitables y el n煤mero de acciones a emitir al ejercerse puede variar con cambios en las acciones ordinarias en circulaci贸n. Los valores declarados son propiedad directa de clientes asesorados por Suvretta, y las personas que informan renuncian a la condici贸n de propietarios beneficiarios salvo en la medida de su inter茅s pecuniario.
Aura Biosciences 瓿奠嫓: Suvretta Capital Management, LLC, Averill Master Fund, Ltd. 氚� Aaron Cowen鞚� Aura Biosciences 氤错喌欤检棎 雽�頃� 瓿惦彊 鞁れ 氤挫湢 歆�攵勳潉 氤搓碃頃╇媹雼�. Suvretta鞕� Aaron Cowen鞚� 臧侁皝 4,701,775欤� (韥措灅鞀れ潣 7.6%)毳� 氤搓碃頃橁碃, Averill Master Fund電� 4,137,797欤� (韥措灅鞀れ潣 6.6%)毳� 氤搓碃頃╇媹雼�. 臧� 氤搓碃鞚胳潃 雼弲 鞚橁舶甓� 霕愲姅 觳橂秳甓岇澊 鞐嗢潓鞚� 氚濏瀳氅� 氤搓碃霅� 欤检嫕鞐� 雽�頃� 瓿惦彊鞚� 鞚橁舶甓� 氚� 觳橂秳甓岇潉 氤搓碃頃╇媹雼�. 鞝滌稖靹滊電� 頄夓偓 臧�電ロ暅 頂勲Μ韼�霐旊摐(靹犽偐) 鞗岆煱韸戈皜 斓滊寑 牍勳湪 靸來暅 9.99%鞚� 鞝侅毄鞚� 氚涭溂氅�, 靹滊┐ 韱奠搿� 61鞚� 頉勳棎 須牓鞚� 氚滌儩頃橂弰搿� 斓滊寑 19.99%旯岇 靸來枼霅� 靾� 鞛堨潓鞚� 靹る獏頃╇媹雼�; 霐半澕靹� 氇摖 鞗岆煱韸戈皜 順勳灛 頄夓偓 臧�電ロ暅 瓴冹潃 鞎勲媹氅�, 頄夓偓 鞁� 氚滍枆霅� 欤检嫕 靾橂姅 鞙犿喌 欷戩澑 氤错喌欤� 靾橃潣 氤�霃欖棎 霐半澕 雼澕歆� 靾� 鞛堨姷雼堧嫟. 氤搓碃霅� 歃濌秾鞚� Suvretta鞚� 鞛愲 瓿犼皾鞚� 歆侅爲 靻岇湢頃橁碃 鞛堨溂氅�, 氤搓碃鞚鸽摛鞚� 鞛愳嫚鞚� 旮堨爠鞝� 鞚挫澋 氩旍渼毳� 齑堦臣頃橂姅 鞁れ鞝� 靻岇湢甓岇潉 欤检灔頃橃 鞎婌姷雼堧嫟.
Divulgation d'Aura Biosciences : Suvretta Capital Management, LLC, Averill Master Fund, Ltd. et Aaron Cowen d茅clarent des positions de propri茅t茅 b茅n茅ficiaire partag茅e sur les actions ordinaires d'Aura Biosciences. Suvretta et Aaron Cowen d茅clarent chacun 4,701,775 actions (7.6% de la cat茅gorie) ; Averill Master Fund d茅clare 4,137,797 actions (6.6% de la cat茅gorie). Chaque d茅clarant indique ne pas d茅tenir de pouvoir exclusif de vote ou de disposition et d茅clare disposer de pouvoirs partag茅s de vote et de disposition sur les actions indiqu茅es. Le dossier d茅crit des warrants pr茅financ茅s exer莽ables soumis 脿 un plafond de Pourcentage Maximum de 9.99%, susceptible d'锚tre port茅 脿 19.99% par avis 茅crit prenant effet apr猫s 61 jours ; par cons茅quent, tous les warrants ne sont pas actuellement exer莽ables et le nombre d'actions susceptibles d'锚tre 茅mises 脿 l'exercice peut varier en fonction des modifications du nombre d'actions ordinaires en circulation. Les titres d茅clar茅s sont d茅tenus directement par des clients conseill茅s par Suvretta, et les d茅clarants d茅clinent la qualit茅 de propri茅taire b茅n茅ficiaire, sauf dans la mesure de leur int茅r锚t p茅cuniaire.
Aura Biosciences-Offenlegung: Suvretta Capital Management, LLC, Averill Master Fund, Ltd. und Aaron Cowen melden gemeinsame wirtschaftliche Eigentumspositionen an den Stammaktien von Aura Biosciences. Suvretta und Aaron Cowen geben jeweils 4,701,775 Aktien (7,6% der Klasse) an; Averill Master Fund meldet 4,137,797 Aktien (6,6% der Klasse). Jede meldende Person erkl盲rt, keine alleinige Stimm- oder Verf眉gungsgewalt zu haben, und meldet gemeinsame Stimm- und Verf眉gungsgewalt f眉r die angegebenen Aktien. Die Einreichung beschreibt vorfinanzierte Warrants, deren Aus眉bung einer Obergrenze in Form eines Maximalen Prozentsatzes von 9.99% unterliegt, die durch schriftliche Mitteilung nach 61 Tagen auf bis zu 19.99% erh枚ht werden kann; folglich sind nicht alle Warrants derzeit aus眉bbar und die Zahl der bei Aus眉bung auszugebenden Aktien kann sich mit 脛nderungen der ausstehenden Stammaktien 盲ndern. Die gemeldeten Wertpapiere werden unmittelbar von Beratungskunden von Suvretta gehalten, und die meldenden Personen weisen eine wirtschaftliche Eigent眉merschaft zur眉ck, au脽er hinsichtlich ihres geldwerten Interesses.
- Material stakes disclosed: Suvretta and Aaron Cowen each report 4,701,775 shares (7.6%) and Averill reports 4,137,797 shares (6.6%).
- Pre-funded warrants present potential additional equity: Warrants can be exercised subject to a defined Maximum Percentage framework, offering structured upside.
- Passive filing form: The Schedule 13G filing and certifications indicate the reported positions are presented as passive holdings rather than an intent to change control.
- No sole voting or dispositive power: Each reporting person reports 0 sole voting and dispositive power, limiting unilateral governance influence.
- Warrants not fully exercisable now: The pre-funded warrants are constrained by a 9.99% exercisability cap, and not all are presently exercisable, which limits immediate conversion/dilution.
- Beneficial ownership disclaimer: Reporting persons disclaim beneficial ownership except for pecuniary interest, which may complicate assessments of true economic control.
Insights
TL;DR: Three affiliated reporting persons hold meaningful stakes (6.6%鈥�7.6%) with shared control and limited immediate exercisability of pre-funded warrants.
The filing shows Suvretta, Averill and Aaron Cowen as reporting persons with shared voting and dispositive power over material stakes: Suvretta and Cowen each report 4,701,775 shares (7.6%) while Averill reports 4,137,797 shares (6.6%). Important for capitalization and potential dilution: pre-funded warrants exist but are subject to a 9.99% exercisability cap (which the holder may increase up to 19.99% after notice), so immediate conversion is constrained and the future share count from exercises may vary with outstanding common stock. The Schedule 13G format and the certification indicate a passive reporting intent rather than an intent to change control.
TL;DR: Shared voting/dispositive power over >6% stakes plus capped pre-funded warrants creates potential influence but with clear contractual limits on exercise and conversion.
The report highlights shared鈥攔ather than sole鈥攃ontrol over the reported positions, which limits unilateral governance actions by any single reporting person. The pre-funded warrants introduce conditional upside but are explicitly limited by a Maximum Percentage constraint (9.99% initial cap, expandable to 19.99% after notice), and the filing states not all warrants are presently exercisable because of this restriction. Additionally, the securities are held by Suvretta advisory clients, and the reporting persons include disclaimers of beneficial ownership except for pecuniary interest, which is relevant when assessing immediate governance implications.
Divulgazione di Aura Biosciences: Suvretta Capital Management, LLC, Averill Master Fund, Ltd. e Aaron Cowen dichiarano posizioni di propriet脿 beneficiaria condivisa sulle azioni ordinarie di Aura Biosciences. Suvretta e Aaron Cowen riportano ciascuno 4,701,775 azioni (7.6% della classe); Averill Master Fund riporta 4,137,797 azioni (6.6% della classe). Ciascuna parte segnalante dichiara di non avere potere di voto o di disposizione esclusivo e indica di detenere congiuntamente il potere di voto e di disposizione sulle azioni indicate. Il deposito descrive warrant prefinanziati esercitabili soggetti a un limite di Percentuale Massima del 9.99%, che pu貌 essere aumentato fino al 19.99% tramite avviso scritto che diventa efficace dopo 61 giorni; di conseguenza non tutti i warrant sono attualmente esercitabili e il numero di azioni emettibili al momento dell'esercizio pu貌 variare con le modifiche delle azioni ordinarie in circolazione. I titoli segnalati sono di propriet脿 diretta dei clienti consuliti di Suvretta, e le persone che segnalano rinunciano a dichiarare la propriet脿 beneficiaria, salvo nella misura del loro interesse pecuniario.
Divulgaci贸n de Aura Biosciences: Suvretta Capital Management, LLC, Averill Master Fund, Ltd. y Aaron Cowen informan posiciones de propiedad beneficiaria compartida sobre acciones ordinarias de Aura Biosciences. Suvretta y Aaron Cowen informan cada uno de 4,701,775 acciones (7.6% de la clase); Averill Master Fund informa 4,137,797 acciones (6.6% de la clase). Cada persona declarantes se帽ala que no tiene poder exclusivo de voto o de disposici贸n y declara tener poderes compartidos de voto y de disposici贸n sobre las acciones indicadas. La presentaci贸n describe warrants prefinanciados ejercitables sujetos a un tope de Porcentaje M谩ximo del 9.99%, que puede incrementarse hasta 19.99% mediante aviso escrito que surte efecto despu茅s de 61 d铆as; por tanto, no todos los warrants son actualmente ejercitables y el n煤mero de acciones a emitir al ejercerse puede variar con cambios en las acciones ordinarias en circulaci贸n. Los valores declarados son propiedad directa de clientes asesorados por Suvretta, y las personas que informan renuncian a la condici贸n de propietarios beneficiarios salvo en la medida de su inter茅s pecuniario.
Aura Biosciences 瓿奠嫓: Suvretta Capital Management, LLC, Averill Master Fund, Ltd. 氚� Aaron Cowen鞚� Aura Biosciences 氤错喌欤检棎 雽�頃� 瓿惦彊 鞁れ 氤挫湢 歆�攵勳潉 氤搓碃頃╇媹雼�. Suvretta鞕� Aaron Cowen鞚� 臧侁皝 4,701,775欤� (韥措灅鞀れ潣 7.6%)毳� 氤搓碃頃橁碃, Averill Master Fund電� 4,137,797欤� (韥措灅鞀れ潣 6.6%)毳� 氤搓碃頃╇媹雼�. 臧� 氤搓碃鞚胳潃 雼弲 鞚橁舶甓� 霕愲姅 觳橂秳甓岇澊 鞐嗢潓鞚� 氚濏瀳氅� 氤搓碃霅� 欤检嫕鞐� 雽�頃� 瓿惦彊鞚� 鞚橁舶甓� 氚� 觳橂秳甓岇潉 氤搓碃頃╇媹雼�. 鞝滌稖靹滊電� 頄夓偓 臧�電ロ暅 頂勲Μ韼�霐旊摐(靹犽偐) 鞗岆煱韸戈皜 斓滊寑 牍勳湪 靸來暅 9.99%鞚� 鞝侅毄鞚� 氚涭溂氅�, 靹滊┐ 韱奠搿� 61鞚� 頉勳棎 須牓鞚� 氚滌儩頃橂弰搿� 斓滊寑 19.99%旯岇 靸來枼霅� 靾� 鞛堨潓鞚� 靹る獏頃╇媹雼�; 霐半澕靹� 氇摖 鞗岆煱韸戈皜 順勳灛 頄夓偓 臧�電ロ暅 瓴冹潃 鞎勲媹氅�, 頄夓偓 鞁� 氚滍枆霅� 欤检嫕 靾橂姅 鞙犿喌 欷戩澑 氤错喌欤� 靾橃潣 氤�霃欖棎 霐半澕 雼澕歆� 靾� 鞛堨姷雼堧嫟. 氤搓碃霅� 歃濌秾鞚� Suvretta鞚� 鞛愲 瓿犼皾鞚� 歆侅爲 靻岇湢頃橁碃 鞛堨溂氅�, 氤搓碃鞚鸽摛鞚� 鞛愳嫚鞚� 旮堨爠鞝� 鞚挫澋 氩旍渼毳� 齑堦臣頃橂姅 鞁れ鞝� 靻岇湢甓岇潉 欤检灔頃橃 鞎婌姷雼堧嫟.
Divulgation d'Aura Biosciences : Suvretta Capital Management, LLC, Averill Master Fund, Ltd. et Aaron Cowen d茅clarent des positions de propri茅t茅 b茅n茅ficiaire partag茅e sur les actions ordinaires d'Aura Biosciences. Suvretta et Aaron Cowen d茅clarent chacun 4,701,775 actions (7.6% de la cat茅gorie) ; Averill Master Fund d茅clare 4,137,797 actions (6.6% de la cat茅gorie). Chaque d茅clarant indique ne pas d茅tenir de pouvoir exclusif de vote ou de disposition et d茅clare disposer de pouvoirs partag茅s de vote et de disposition sur les actions indiqu茅es. Le dossier d茅crit des warrants pr茅financ茅s exer莽ables soumis 脿 un plafond de Pourcentage Maximum de 9.99%, susceptible d'锚tre port茅 脿 19.99% par avis 茅crit prenant effet apr猫s 61 jours ; par cons茅quent, tous les warrants ne sont pas actuellement exer莽ables et le nombre d'actions susceptibles d'锚tre 茅mises 脿 l'exercice peut varier en fonction des modifications du nombre d'actions ordinaires en circulation. Les titres d茅clar茅s sont d茅tenus directement par des clients conseill茅s par Suvretta, et les d茅clarants d茅clinent la qualit茅 de propri茅taire b茅n茅ficiaire, sauf dans la mesure de leur int茅r锚t p茅cuniaire.
Aura Biosciences-Offenlegung: Suvretta Capital Management, LLC, Averill Master Fund, Ltd. und Aaron Cowen melden gemeinsame wirtschaftliche Eigentumspositionen an den Stammaktien von Aura Biosciences. Suvretta und Aaron Cowen geben jeweils 4,701,775 Aktien (7,6% der Klasse) an; Averill Master Fund meldet 4,137,797 Aktien (6,6% der Klasse). Jede meldende Person erkl盲rt, keine alleinige Stimm- oder Verf眉gungsgewalt zu haben, und meldet gemeinsame Stimm- und Verf眉gungsgewalt f眉r die angegebenen Aktien. Die Einreichung beschreibt vorfinanzierte Warrants, deren Aus眉bung einer Obergrenze in Form eines Maximalen Prozentsatzes von 9.99% unterliegt, die durch schriftliche Mitteilung nach 61 Tagen auf bis zu 19.99% erh枚ht werden kann; folglich sind nicht alle Warrants derzeit aus眉bbar und die Zahl der bei Aus眉bung auszugebenden Aktien kann sich mit 脛nderungen der ausstehenden Stammaktien 盲ndern. Die gemeldeten Wertpapiere werden unmittelbar von Beratungskunden von Suvretta gehalten, und die meldenden Personen weisen eine wirtschaftliche Eigent眉merschaft zur眉ck, au脽er hinsichtlich ihres geldwerten Interesses.
FAQ
How many AURA shares does Suvretta Capital report owning?
What stake does Averill Master Fund hold in Aura Biosciences (AURA)?
Do the reporting persons have sole voting or dispositive power over the shares?
What are the key terms of the pre-funded warrants mentioned in the filing?
Are the reported securities owned directly or on behalf of others?
